title: Burden of disease matters when it comes to systemic therapy for prostate cancer.
authors.affiliation: Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. Electronic address: michael.harrison@duke.edu.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Harrison
authors.affiliation: Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA; Department of Surgery, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Armstrong
mesh_terms: D000069501:Abiraterone Acetate / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D065607:Cytochrome P-450 Enzyme Inhibitors / Q000627:therapeutic use*; D006304:Health Status; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D065088:Steroid Synthesis Inhibitors / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D065607:Cytochrome P-450 Enzyme Inhibitors; D065088:Steroid Synthesis Inhibitors; D000069501:Abiraterone Acetate